Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants
Gain Therapeutics, Inc. (GANX)
Company Research
Source: GlobeNewswire
BETHESDA, Md., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing of an underwritten public offering of 2,213,044 shares of its common stock and warrants to purchase up to an aggregate of 1,106,522 shares of its common stock at a combined public offering price of $2.005 per share and accompanying warrant. The public offering price for each set of two shares of common stock and accompanying warrant to purchase one share of common stock is $4.01 per set of securities, yielding an effective price of $2.00 per share and $0.01 per warrant. The warrants are being sold at the rate of one warrant for every two shares of common stock. The warrants will have an exercise price of $2.75 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. In connection with the offering, Gain has granted the underwriters a 30-day option to purchase up to an additional 15% of s
Show less
Read more
Impact Snapshot
Event Time:
GANX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GANX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GANX alerts
High impacting Gain Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GANX
News
- Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at Roth Capital.MarketBeat
- Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s DiseaseGlobeNewswire
- Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease [Yahoo! Finance]Yahoo! Finance
- Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s DiseaseGlobeNewswire
GANX
Sec Filings
- 12/18/25 - Form 8-K
- 12/3/25 - Form S-8
- 11/28/25 - Form 8-K
- GANX's page on the SEC website